Peptides DB

Research-centric peptide and protocol reference hub

BPC-157 vs GHK-Cu

Updated July 21, 2026 · Reviewed by the PeptidesDB Editorial team

BPC-157: Research use — not FDA-approvedGHK-Cu: Research use — not FDA-approved

A data-driven comparison of BPC-157 and GHK-Cu (also searched as GHK-Cu vs BPC-157) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.

Verdict

BPC-157 centers on healing, while GHK-Cu leans toward skin. On indexed research, BPC-157 is ahead (BPC-157: 6 studies, Human evidence; GHK-Cu: 5, Preclinical). Choose by goal — and read the primary studies. This is research information, not medical advice.

Key takeaways

  • BPC-157 is strongest for healing; GHK-Cu for skin.
  • Evidence: BPC-157 Human evidence (6 studies) vs GHK-Cu Preclinical (5).
  • Both are research-use compounds — not FDA-approved.

Effect profiles, overlaid

HealingMuscleMetabolicNeuroSleepInflammationSkin
BPC-157GHK-Cu

At a glance

BPC-157Human evidence

Body Protection Compound-157 | Pentadecapeptide

Strongest: HealingStudies: 6Level: Extensively Studied
GHK-CuPreclinical

Copper Peptide | Skin Regeneration & Anti-Aging Compound

Strongest: SkinStudies: 5Level: Well Studied

BPC-157 vs GHK-Cu: side-by-side

MetricBPC-157GHK-Cu
ClassHealingSkin
Regulatory statusResearch use onlyResearch use only
Evidence gradeHuman evidencePreclinical
Studies indexed65
Research levelExtensively StudiedWell Studied
Strongest effectHealing & recoverySkin & aesthetics
Healing & recovery4.34.0
Muscle & body comp3.31.0
Metabolic & appetite2.33.0
Neuro & mood3.02.0
Sleep & circadian0.70.0
Inflammation & immune4.04.0
Skin & aesthetics2.05.0

▲ marks the higher community effect score (0–5 perceived-effect signal, not clinical efficacy).

Mechanism & pharmacokinetics

PropertyBPC-157GHK-Cu
MechanismBody-protective compound (pentadecapeptide); cytoprotective, pro-angiogenic signalingCopper-binding tripeptide (GHK-Cu); tissue-remodeling / regenerative signaling
RouteSubcutaneous / oral (research use)Topical / subcutaneous

Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.

What is BPC-157?

Body Protective Compound often discussed for soft-tissue repair, GI support, and inflammation modulation.

Full BPC-157 profile, mechanism & studies →

What is GHK-Cu?

Copper-binding tripeptide widely used in skin, hair, and wound-healing contexts, with systemic effects explored in research.

Full GHK-Cu profile, mechanism & studies →

Which is better for your goal?

GoalBetter fitWhy
HealingBPC-1574.3/5 effect signal
MuscleBPC-1573.3/5 effect signal
MetabolicGHK-Cu3.0/5 effect signal
NeuroBPC-1573.0/5 effect signal
SleepBPC-1570.7/5 effect signal
InflammationEvenBoth ~4.0/5
SkinGHK-Cu5.0/5 effect signal

Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.

Can you stack BPC-157 and GHK-Cu?

People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because neither compound is FDA-approved, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.

BPC-157 vs GHK-Cu: side effects

BPC-157
  • improved healing28
  • flushing14
  • vivid dreams11
  • nausea3
  • anxiety2
GHK-Cu
  • improved skin texture18
  • localized irritation5
  • transient tingling4
  • gi upset1
  • headache1

Anonymous community reports (count = number of reports), not clinical incidence rates.

What the research says

BPC-157 has 6 approved studies indexed (Human evidence), and GHK-Cu has 5 (Preclinical). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.

Frequently asked questions

Is BPC-157 or GHK-Cu better?

It depends on your goal. BPC-157 is strongest for healing; GHK-Cu for skin. BPC-157 has more indexed studies (6). See the goal-by-goal breakdown above.

Is BPC-157 or GHK-Cu better for weight loss?

GHK-Cu shows the stronger metabolic & appetite profile (3.0/5) in community effect data — though weight-loss outcomes depend on the individual and the evidence base.

Is BPC-157 or GHK-Cu better for muscle?

BPC-157 leads on the muscle & body-composition axis (3.3/5).

Which has more research, BPC-157 or GHK-Cu?

BPC-157 has 6 approved studies indexed (Human evidence); GHK-Cu has 5 (Preclinical). Higher counts mean more to read, not proven superiority.

Can you stack BPC-157 and GHK-Cu?

Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.

What are the side effects of BPC-157 vs GHK-Cu?

BPC-157: community-reported improved healing, flushing, vivid dreams. GHK-Cu: improved skin texture, localized irritation, transient tingling. These are anonymous reports, not incidence rates — see each profile.

Is BPC-157 or GHK-Cu FDA-approved?

BPC-157 is a research-use compound and is not FDA-approved. GHK-Cu is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.

Is GHK-Cu better than BPC-157?

For skin, GHK-Cu has the edge; for healing, BPC-157 does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.

Comparing related peptides

Regulatory & legal status

BPC-157 and GHK-Cu are research-use compounds and are not FDA-approved for human use. FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed July 21, 2026.